New Pancreatic Cancer Drug Doubles Survival in Trials

Oncologists gave researchers a standing ovation when they announced results that could transform treatment for one of the deadliest cancers. A new drug called daraxonrasib doubled survival time for patients with advanced pancreatic cancer, extending it from 6.7 months to 13.2 months in a study of 500 patients.

Ten Intermountain Health hospitals in Utah, Colorado, and Montana are now providing early access to this treatment through an FDA-approved program. Patients with advanced pancreatic cancer who have exhausted other options may be eligible to receive the drug before it becomes widely available.

"This is a true paradigm shift in how we treat pancreatic cancer," said Dr. Mark Lewis, director of gastrointestinal oncology at Intermountain Health. "I can't remember the last time I saw such a positive leap forward in the treatment of this terrible disease."

Pancreatic cancer kills more than 52,000 Americans annually, making it the third leading cause of cancer deaths in the United States. It's particularly challenging because it rarely causes noticeable symptoms until advanced stages, when the disease is typically incurable.

The new treatment works differently than traditional chemotherapy by targeting specific genetic mutations that drive tumor growth. Daraxonrasib shuts down growth signals from mutated KRAS genes, which are present in over 90% of pancreatic cancers and cause cells to multiply uncontrollably.

Patients take the medication orally once daily. While it doesn't cure pancreatic cancer, it represents a major advancement in giving patients more time with their families and better quality of life.

The Ripple Effect

This breakthrough extends beyond major research centers. Smaller communities in Colorado, Montana, and Utah now have access to cutting-edge cancer treatment that was previously only available through limited clinical trials.

"We are thrilled to have early access to a promising and desperately needed therapy for our patients," said Dr. Ned Jones, an oncologist at Intermountain St. Mary's Hospital in Grand Junction, Colorado. Access to advanced therapies in smaller communities means patients can receive life-extending treatment close to home.

The drug represents a growing shift toward precision medicine, where treatments are tailored to each patient's unique cancer genetics. This personalized approach is opening new doors for diseases that have long resisted traditional treatments.

For the 67,000 Americans diagnosed with pancreatic cancer each year, this advancement brings something that's been scarce: hope.